The optic nerve is commonly involved in multiple sclerosis (MS). Acute optic neuritis (ON) is the initial manifestation of MS in 25% of patients; optic neuropathy is frequently evident during the course of the disease and the optic nerve is nearly universally involved at autopsy. 1 Yet, despite the well-established associations of optic nerve disease with MS, the optic nerve fails to play a major role in the diagnostic criteria for MS today. As the diagnosis of MS has evolved to incorporate magnetic resonance imaging (MRI) criteria that may substitute for clinical criteria for diagnosis, the tail has begun to wag the dog. The diagnostic criteria have become heavily reliant on the results of MRI studies. 2 Since we lack MRI evidence showing that an asymptomatic lesion of optic nerve adds to the sensitivity and specificity for the diagnosis of definite MS, the optic nerve has largely been cast aside as a lesion site for dissemination in space. This is true despite the enormous help provided by ON in the diagnosis of MS and its ability to distinguish common disorders in the differential diagnosis of MS, such as migraine and microvascular ischemic disease.
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Today, the diagnosis of an optic nerve lesion can be established by clinical criteria, including visual field loss, an afferent pupillary defect, and the presence of pain on eye movement. Optic nerve involvement may be also verified by electrophysiological criteria or MRI; but, perhaps, the most important tool available today is optical coherence tomography (OCT). MRI scans commonly visualize an optic nerve that is symptomatically involved (as in acute ON), but very rarely does one see changes on MRI supporting asymptomatic involvement of the optic nerve. 3, 4 There is the rub! Dedicated MRI of the orbits with fat-saturated images is helpful, but imperfect and still dependent on search coils and variability of protocols that provide images of optic nerve. So, even excellent orbital MRI protocols can miss subtle changes in the optic nerve. OCT has approximately a 1000-fold resolution compared to MRI, so it should no surprise that asymptomatic optic nerve involvement is commonly found using this technique in patients with MS. 5, 6 The current diagnostic criteria for MS do not allow OCT measurements or asymptomatic MRI abnormalities in the optic nerve to count for dissemination in space. This leads to many diagnostic inconsistencies for clinicians. First, a symptomatic enhancing brainstem or spinal cord lesion and one non-enhancing periventricular lesion can now qualify for the diagnosis of MS. By the new criteria, the symptomatic brainstem or spinal cord lesion can count as a site of enhancement (dissemination in time) and for dissemination space. This is not true for the optic nerve. Thus, a patient can have a symptomatic and enhancing optic nerve by MRI, and the exact same periventricular lesion described above, and not qualify for the diagnosis of MS. So, we are now in the diagnostic paradigm where the site of the mono-symptomatic presentation is regarded differentially for MS diagnosis, and brainstem and spinal cord lesions seemingly having more importance than an optic nerve lesion. Previous diagnostic criteria had excluded counting the lesion site for dissemination in time and space, but new evidence suggests that counting the symptomatic brainstem or spinal cord lesion may increase the sensitivity for the diagnosis of MS without losing specificity. 7 The evidence for not including the optic nerve in the new diagnostic paradigms is scant-and the absence of proof cannot equal the proof of absence. Unfortunately, we just don't have solid evidence right now about how the symptomatic enhancing optic nerve should be counted. Nonetheless, we know from natural history studies and clinical trial results that the location of the mono-symptomatic event does not by itself predict future clinical demyelinating events
The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS -Yes
when the baseline brain MRI shows evidence of other white matter lesions. [8] [9] [10] The second problem with the current criteria is that they exclude the optic nerve as an asymptomatic lesion site for dissemination in space. In the current criteria, we could detect asymptomatic brain lesions that may help qualify the patient for MS diagnosis by dissemination in time and space. Again, this is not the case for an optic nerve lesion. For instance, if a patient with a symptomatic brainstem lesion had an otherwise-normal brain MRI, the new appearance of an asymptomatic periventricular lesion or other new brain lesion would qualify that patient for the diagnosis of MS; however, a new asymptomatic optic nerve lesion as determined by imaging or electrophysiological criteria would not meet criteria for MS diagnosis.
With every debate, there comes a new opportunity for investigation. We now have to collaborate and combine our resources to determine the future of the optic nerve as an asymptomatic lesion site for dissemination in space to be used in the diagnosis of MS. What do we need now? We need to verify the cutoffs for inter-eye differences using OCT measures of retinal nerve fiber layer (RNFL) thickness following acute ON to establish the diagnosis of a new asymptomatic optic nerve lesion. This might be the most reliable criterion to determine an optic nerve lesion by OCT, particularly since absolute loss of RNFL thickness following ON versus the same inter-eye difference measurements in disease-free controls should be reasonably balanced with regard to history of myopia, for example. Information about what constitutes an optic nerve lesion using absolute values and inter-eye differences will be critical. As with any new candidate criterion for an optic nerve lesion, we must test the average inter-eye differences in validation cohorts of patients with clinically isolated syndromes and with MS and history of acute ON. These analyses can determine how the optic nerve inter-eye differences can predict conversion to definite MS and predict which patients with MS have a history of acute unilateral ON. Even if the optic nerve cannot be established as an important imaging lesion site by MRI in the current diagnostic criteria, this important and myelinated tract of the brain will always be important as a clinical component of MS and invaluable in sorting out the differential diagnosis for those patients presenting with neurological symptoms and white matter changes on MRI. The optic nerve is an unsung hero in the diagnosis of MS, and "seeing is believing."
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